{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Lymphoid+Cancer", "query": { "condition": "B-cell Lymphoid Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1829, "total_pages": 183, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Lymphoid+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-24T21:18:37.038Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02258555", "title": "Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Follicular Lymphoma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "GS-9901", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2015-01", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2015-10-19", "last_synced_at": "2026-07-24T21:18:37.038Z", "location_count": 6, "location_summary": "Duarte, California • Fresno, California • Whittier, California + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Southington", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02258555" }, { "nct_id": "NCT01429025", "title": "Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory/Relapsed Indolent Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bendamustine", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2012-05", "completion_date": "2019-07-01", "has_results": false, "last_update_posted_date": "2019-10-08", "last_synced_at": "2026-07-24T21:18:37.038Z", "location_count": 17, "location_summary": "Clive, Iowa • Des Moines, Iowa • Sioux City, Iowa + 3 more", "locations": [ { "city": "Clive", "state": "Iowa" }, { "city": "Clive", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01429025" }, { "nct_id": "NCT04049383", "title": "CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia, in Relapse", "Acute Lymphoblastic Leukemia With Failed Remission", "Acute Lymphoblastic Leukemia Recurrent", "Acute Lymphoblastic Leukemia Not Having Achieved Remission", "Acute Lymphoblastic Leukemia, Pediatric", "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg)", "type": "BIOLOGICAL" }, { "name": "CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg)", "type": "BIOLOGICAL" }, { "name": "CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)", "type": "BIOLOGICAL" }, { "name": "CAR-20/19-T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "70 Years", "sex": "ALL", "summary": "1 Year to 70 Years" }, "enrollment_count": 5, "start_date": "2020-10-16", "completion_date": "2025-09-01", "has_results": false, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-07-24T21:18:37.038Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04049383" }, { "nct_id": "NCT01110473", "title": "ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myelogenous Leukemia", "B-cell Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Myelodysplasia" ], "interventions": [ { "name": "ABT-348", "type": "DRUG" }, { "name": "ABT-348 and azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 52, "start_date": "2010-04", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2017-11-20", "last_synced_at": "2026-07-24T21:18:37.038Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Houston, Texas", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01110473" }, { "nct_id": "NCT01676805", "title": "Tissue Collection for Studies of Lymph Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hodgkin Disease", "Lymphoma, Non-Hodgkin", "Multiple Myeloma", "Lymphomatoid Granulomatosis", "Leukemia-Lymphoma, Adult T-Cell" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1295, "start_date": "2012-09-21", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-07-24T21:18:37.038Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01676805" }, { "nct_id": "NCT00003829", "title": "Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "1999-08", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2016-12-07", "last_synced_at": "2026-07-24T21:18:37.038Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003829" }, { "nct_id": "NCT00121186", "title": "S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2005-07", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2012-04-03", "last_synced_at": "2026-07-24T21:18:37.038Z", "location_count": 33, "location_summary": "Maywood, Illinois • Beech Grove, Indiana • Richmond, Indiana + 20 more", "locations": [ { "city": "Maywood", "state": "Illinois" }, { "city": "Beech Grove", "state": "Indiana" }, { "city": "Richmond", "state": "Indiana" }, { "city": "Chanute", "state": "Kansas" }, { "city": "Dodge City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00121186" }, { "nct_id": "NCT02727803", "title": "Personalized NK Cell Therapy in CBT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Biphenotypic Leukemia", "Acute Lymphoblastic Leukemia", "Acute Lymphoblastic Leukemia in Remission", "Acute Myeloid Leukemia With Myelodysplasia-Related Changes", "Acute Myeloid Leukemia With Variant MLL Translocations", "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "Chemotherapy-Related Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "ISS Stage II Plasma Cell Myeloma", "ISS Stage III Plasma Cell Myeloma", "Myelodysplastic Syndrome", "Myelodysplastic Syndrome With Excess Blasts", "Myelodysplastic Syndrome With Gene Mutation", "Myelodysplastic/Myeloproliferative Neoplasm", "Previously Treated Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Hodgkin Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Adult Acute Lymphoblastic Leukemia", "Secondary Acute Myeloid Leukemia", "Therapy-Related Myelodysplastic Syndrome" ], "interventions": [ { "name": "Allogeneic Natural Killer Cell Line NK-92", "type": "BIOLOGICAL" }, { "name": "Anti-Thymocyte Globulin", "type": "BIOLOGICAL" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Umbilical Cord Blood Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "RADIATION", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "15 Years to 80 Years" }, "enrollment_count": 100, "start_date": "2016-05-19", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-07-24T21:18:37.038Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02727803" }, { "nct_id": "NCT00002880", "title": "Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Etoposide phosphate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 53, "start_date": "1996-11", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2016-06-28", "last_synced_at": "2026-07-24T21:18:37.038Z", "location_count": 4, "location_summary": "Minneapolis, Minnesota • St Louis, Missouri • Paterson, New Jersey + 1 more", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Paterson", "state": "New Jersey" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002880" }, { "nct_id": "NCT00499239", "title": "A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "GS-9219", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2007-07", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2014-02-04", "last_synced_at": "2026-07-24T21:18:37.038Z", "location_count": 5, "location_summary": "San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499239" } ] }